Earnings Feed
Start Free
Beam Therapeutics Inc.·4

Jul 1, 4:05 PM ET

Evans John M. 4

Research Summary

AI-generated summary

Updated

Beam Therapeutics CEO John M. Evans Exercises Options, Sells Shares

What Happened

  • John M. Evans, CEO and Director of Beam Therapeutics (BEAM), exercised a total of 50,000 option-derived shares (18,663 @ $0.67; 6,337 @ $1.03; 25,000 @ $1.03) for a combined exercise cost of $44,781, and sold 50,000 common shares in open-market transactions for aggregate proceeds of approximately $1,745,037. The sales occurred on June 29–30, 2026 and were carried out under a Rule 10b5-1 trading plan.

Key Details

  • Transaction dates: June 29, 2026 (exercises and some sales) and June 30, 2026 (exercise and sales).
  • Exercises (acquisitions): 18,663 @ $0.67 ($12,504); 6,337 @ $1.03 ($6,527); 25,000 @ $1.03 ($25,750). Some derivative entries are shown as $0 in the filing to reflect conversion/derivative reporting.
  • Sales (dispositions): 13,421 @ $35.13 (Wtd avg; range $34.55–$35.50); 11,579 @ $35.91 (Wtd avg; range $35.60–$36.18); 23,100 @ $34.26 (Wtd avg; range $33.80–$34.71); 1,900 @ $34.84 (Wtd avg; range $34.83–$34.85). Total shares sold = 50,000; total proceeds ≈ $1,745,037.
  • Shares owned after transaction: not specified in the provided excerpt of the filing — see the full Form 4 for total post-transaction holdings.
  • Notable footnotes: sales were made pursuant to a Rule 10b5-1 plan adopted May 16, 2025 (F1). Several sale prices are reported as weighted averages with provided price ranges (F2–F5). Earlier option grants and vesting details are noted in the filing (F6, F7).
  • Filing timeliness: no late-filing indication in the provided data.

Context

  • This was an option exercise immediately followed by market sales — commonly called a cashless or simultaneous exercise-and-sell under a 10b5-1 plan, which is a prearranged program allowing scheduled sales even for insiders.
  • Such transactions are often routine liquidity events for insiders rather than an explicit signal about company outlook; purchases typically carry more weight as a bullish indicator. For full details (exact per-trade prices, total holdings before/after, and any tax withholdings), consult the full SEC Form 4 (Accession 0001193125-26-292526).